Leukocytosis

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

Retrieved on: 
Tuesday, August 2, 2022
Patient, Death, Neutrophilia, Phenotype, GLOBE, Water, LAD, Protein, Forward-looking statement, SEC, FTD, Birth, Biomarker, Probability, Private Securities Litigation Reform Act, SLX, Psychomotor retardation, Leukocytosis, ODD, Glycosylation, Lists of diseases, Therapy, COVID-19, Safety, Efficacy, Multi-system (rail), Quality of life, Drug development, Disease, Company, Nasdaq, Red blood cell, PRV, Program, Glycoprotein, Priority review, API, Hypotonia, CDG, Selectin, Pharmaceutical industry, Crossover, MD

AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).

Key Points: 
  • AVTX-803 is a therapy developed and studied for the treatment of leukocyte adhesion deficiency type II (LAD II, also known as SLC35C1-CDG).
  • We are excited to announce the first patient was dosed in the LADDER pivotal trial.
  • This substantially advances the program toward an approved treatment option for patients and also a potential PRV, said Garry A. Neil, MD, President and Chief Executive Officer, Avalo Therapeutics.
  • The primary endpoint is the comparison of leukocyte function as determined by sialyl Lewis-X (SLx) antigen expression on leukocytes between treatment periods.

ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Retrieved on: 
Thursday, April 7, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, National Association Medical Staff Services, University, Biomarker, Septic, Population, Human, Manifest and latent functions and dysfunctions, Acute kidney injury, Nephrology, Dialysis, Mortality, Research, Medicine, Bed, Health, AKI, Senior, Endothelial dysfunction, Critical care, Sepsis, Transplant, Inflammation, COVID-19, HDL, VP, COVID, Leukocytosis, Patient, Pharmaceutical industry

ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported positive interim results of an open-label Phase 2a clinical trial evaluating CER-001 as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI).

Key Points: 
  • ABIONYX Pharma (FR0012616852 ABNX PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies for patients, today reported positive interim results of an open-label Phase 2a clinical trial evaluating CER-001 as a treatment for septic patients at high risk of developing Acute Kidney Injury (AKI).
  • The RACERS study aims to include 20 patients with gram-negative sepsis who are at high risk for acute kidney injury due to high levels of endotoxin activity and decline in function of one or more organ systems.
  • Compared to standard of care therapy, CER-001 rapidly improved biomarkers of inflammation including leukocytosis, and endothelial dysfunction, preventing septic patients decline into acute kidney injury.
  • Response to CER-001 treatment was rapid, relative to standard of care therapy, with clinical benefit demonstrated as soon as Day 3.

Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)

Retrieved on: 
Wednesday, March 2, 2022
Biotechnology, FDA, Pharmaceutical, Health, Allergy, Fever, Thrombocytopenia, Spleen, Acute myeloid leukemia, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Leukocytosis, BLA, Patient, MDS, Breast, Rupture, Hematopoietic stem cell transplantation, Hair, List of life sciences, Food, Anti-transglutaminase antibodies, Breathe Me, Febrile neutropenia, FDA, Anemia, Kidney, LLC, Blood, Acute respiratory distress syndrome, Anaphylaxis, Glomerulonephritis, Hypoesthesia, Time, AML, Inflammation, Pain, Acute kidney injury, Rash, Nosebleed, Neutrophil, BMT, History, Â, Diarrhea, Fatal, Neutropenia, Factor X, Cough, Radiation, Filgrastim, Incidence, Haematopoietic system, Myelodysplastic syndrome, Generic drug, Fine chemical, Vaccine, Hospital, Dentistry, Pharmaceutical industry, Medical imaging, Amneal Pharmaceuticals

Kashiv Biosciences, LLC (Kashiv) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.

Key Points: 
  • Kashiv Biosciences, LLC (Kashiv) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen.
  • Kashiv is planning for a pegfilgrastim biosimilar referencing Neulasta to also be approved in 2022.
  • It is a proud moment for the Kashiv team and our partners at Amneal to have our first biosimilar, RELEUKO, approved by the U.S. FDA.
  • Kashiv is one of a few domestic companies to manufacture and launch a biosimilar in the United States.

Forma Therapeutics’ Investigational Olutasidenib in Combination with Azacitidine Yields Durable Complete Remission in Patients with mIDH1 Acute Myeloid Leukemia

Retrieved on: 
Thursday, December 16, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Therapy, American Cancer Society, CR, PMID, Anemia, Febrile neutropenia, Dexamethasone, Liver, Nausea, Patient, Vomiting, Leukocytosis, Acute myeloid leukemia, Trial of the century, CRH, HMA, LinkedIn, Cancer, Adult, Constipation, Sickle cell disease, Thrombocytopenia, Blood, Safety, FLT3, Risk, ASH, Society, Degenerative disease, U.S. Securities and Exchange Commission, Forma, IDH1, Cell, Nasdaq, Prostate cancer, COVID-19, SEC, Neutropenia, Research, Prevalence, Mutation, Myelocyte, Poster, AML, Azacitidine, Private Securities Litigation Reform Act, Ganser syndrome, Goal, QT interval, Enzyme, Diarrhea, Pharmaceutical industry, Vaccine, AML, Olutasidenib, Forma Therapeutics, AML, OLUTASIDENIB, FORMA THERAPEUTICS

The findings support the potential of olutasidenib as the basis of combination therapy in patients with AML who have not achieved a durable response from prior therapy.

Key Points: 
  • The findings support the potential of olutasidenib as the basis of combination therapy in patients with AML who have not achieved a durable response from prior therapy.
  • Patients who are not achieving remission or suffer from an AML relapse are in need of new therapies with more durable outcomes.
  • Olutasidenib was well tolerated in the trial in combination with azacitidine and the combination had a safety profile largely consistent with that of olutasidenib alone.
  • Acute myeloid leukemia (AML) is a cancer that starts in a persons bone marrow but often quickly moves into the blood.

$7.86Bn Blood Transfusion Market by 2024 - Analysis on Key Market Dynamics - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2019
Health, Medical Supplies, Medical specialties, Hematology, Blood disorders, Branches of biology, Anatomy, Transfusion medicine, Blood, Blood transfusion, Transfusion, Leukopenia, Grifols, Leukocytosis

The "Blood Transfusion Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Blood Transfusion Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • The most commonly performed surgeries that require blood transfusion include cardiovascular procedures, C-section procedures, and trauma and accident injuries.
  • The rise in the number of blood disorders, such as anemia, leukopenia, erythrocytosis, leukocytosis, and thrombocytosis is also boosting the blood transfusion market.
  • Companies like Immucor Inc., Becton Dickinson, B. Braun, Terumo Corporation, and Grifols SA., hold a significant share in the blood transfusion market.